Nuvation Bio Inc. (NUVB) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$4.70

From 52W high−50.42%

Volume7.97M

Market cap$1.66B

P/E (TTM)—

P/S (TTM)9.8x

Div yield—

Key dataNov 4, 2026

Open

$4.70

From 52W high

−50.42%

Volume

7.97M

Market cap

$1.66B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−9.9x

P/E (TTM)

—

RSI (14)

38.2

MomentumView details →

1D Return

+0.85%

YTD Return

−49.22%

SummaryUpdated Jun 1, 2026

Nuvation Bio Inc. (NASDAQ:NUVB) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in New York, New York. Originally incorporated as RePharmation Inc., the company changed its name to Nuvation Bio Inc. in April 2019 and went public in August 2020. The company focuses on developing innovative therapeutic candidates for oncology, with its lead asset taletrectinib approaching FDA approval with a PDUFA date of June 23, 2025.

Ask drillr about Nuvation Bio Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−9.9x

EV/Sales

7.4x

P/S (TTM)

9.8x

P/B (TTM)

6.5x

ProfitabilityView details →

Gross Margin

93.94%

Net Margin

−88.19%

EBITDA Margin

−74.77%

ROE (TTM)

−59.02%

ROA (TTM)

−20.12%

Asset Turnover

0.25x

GrowthView details →

Revenue YoY

+1083.56%

EPS YoY

+31.03%

FCF YoY

+28.27%

Revenue CAGR 3Y

+698.96%

EPS CAGR 3Y

+71.56%

EBITDA YoY

+36.85%

MomentumView details →

1D Return

+0.85%

YTD Return

−49.22%

1Y Return

−7.52%

RSI (14)

38.2

vs 50D SMA

−17.19%

vs 200D SMA

−15.37%

Capital & dividendView details →

Debt/Equity

0.99x

Current Ratio

8.37x

Quick Ratio

8.14x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.15

EPS Surprise

−5.89%

Beats (12Q)

4/12

Next Q EPS Est

−$0.12

Avg Surprise (4Q)

−24.39%

Rev Surprise

17.24%

Financials snapshotView financials →

Revenue (TTM)

169.90M

Net Income (TTM)

−149.83M

Op. CF (TTM)

−120.52M

Next earningsNov 4, 2026 →

Latest newsMore news →

Nuvation Bio Inc. reported third-quarter 2026 total revenue of $45.0 million, including $27.5 million in net product revenue for IBTROZI.13m ago

Vir Biotechnology, Inc. hired David Liu as chief medical officer.5d ago

Similar companies

Lycia Therapeutics Inc.LYCA Forte Biosciences, Inc.FBRX Ultragenyx Pharmaceutical Inc.RARE Clover Biopharmaceuticals, Ltd.02197.HK 金迪克688670.SH Intellia Therapeutics, Inc.NTLA Find similar companies →

Latest newsMore news →

Nuvation Bio Inc. reported third-quarter 2026 total revenue of $45.0 million, including $27.5 million in net product revenue for IBTROZI.13m ago Vir Biotechnology, Inc. hired David Liu as chief medical officer.5d ago